Stem Cell Clinic

Stem Cell Therapy for Erectile Dysfunction | Stem Cell …

*Note: For the investigational use of Adipose-Derived Stem Cells (ADSCs) for clinical research and deployment.

Erectile Dysfunction (ED) can have an emotional impact on men, affecting both self-confidence and personal relationships. For many years, treatment for ED was palliative in nature and relied on the use of medication in a timely manner. Although popular medications can be successful in enabling an erection in approximately 75% of patients, the inability to be truly spontaneous in intimacy and possible side effects often diminished their true effectiveness. In addition, medications can begin to lose effectiveness or stop working completely when used continuously.

Recent scientific studies have shed light on both the underlying causes of ED and new treatment options that address them, instead of treating only the symptoms. There are exciting new treatment options for men suffering from erectile dysfunction that can provide natural and lasting results without medication, including stem cell therapy. A pioneer in the use of stem cells for regenerative medicine, Dr. Todd Malan offers treatment for ED that uses the bodys own resources to repair damaged tissue and restore your ability to experience sexual satisfaction with a spontaneous erection.

Using stem cells, Dr. Todd Malan is able to help men achieve stronger and longer-lasting erections without the use of medications or external support devices. Stem cells actually repair damaged blood vessels for improved blood flow, making this a truly regenerative treatment.

In the past, erectile dysfunction was believed to be a psychological condition. We now know that there are a number of factors that can contribute to ED. It is a very common condition, affecting as many as 30 million men in the United States. Impotence can affect any man at any age, however, it is more common in older men. The incidence of erectile dysfunction also increases with age. Major risk factors include:

One of the most common reasons for erectile dysfunction is damaged blood vessels and reduced blood flow to the penis, which can be caused by any of the factors above. The ability to achieve and maintain an erection is dependent on the capability of the veins in the penis to respond to certain stimulation. Blood vessels must also be able to maintain dilation for the maintenance of an erection. With age, those veins begin to have micro-damage, which is normal with all blood vessels in every area of the body.

Dr. Malan is able to repair that damage with stem cell therapy so that the blood vessels are able to better respond to a stimulus due to sufficient blood flow and produce a stable, more prominent erection.

The Era of Regenerative Medicine: New Hope for Treating EDIt is estimated that as many as 30 million men in the United States are affected by erectile dysfunction. Past treatments focused on the management of symptoms. Stem cells are being widely used by medical doctors to regenerate damaged tissues and blood vessels. In sports medicine, stems cells are highly effective in repairing musculoskeletal injuries.

Applying this knowledge to the treatment of erectile dysfunction, Dr. Malan and other leading physicians are using stem cells to regenerate damaged blood vessels in the penis. These therapies help men achieve longer-lasting, much larger erections than they would normally be able to achieve. Because stem cells have the ability to replicate themselves, they can actually heal the damaged vessels.

There are many different types of stem cells. For the treatment of erectile dysfunction, three types of adult stem cells are commonly used:

Dr. Malan is a pioneer in the use of ADSC. He has developed a technique that involves the use of advanced liposuction to harvest fat cells and a sophisticated purification process to produce a stem cell-rich gel that is then injected into the blood vessels in the penis.

Why Fat Stem Cells?Harvesting adipose-derived stem cells (ADSCs) is much easier and less invasive than harvesting either bone marrow or muscle-derived stem cells. Fat is abundant in the body and is obtained using minimally invasive liposuction. ADSCs have a significantly higher concentration of mesenchymal stem cells, which have the ability to self-renew, clone, and differentiate into multiple tissues.

This procedure is also referred to as autologous stem cell therapy, which means the donor and the recipient are the same people. Because of the high volume of stem cells found in fat tissue, there is no need to culture the cells or wait for them to grow. They can be harvested, concentrated into a stem cell-rich mixture and re-injected into the treatment area on the same day of the procedure.

Throughout the United States, it is popular among doctors to use liquid-based stem cells. Dr. Malan uses the latest technique, developed in Europe, to use a gel or paste stem cell mixtures, which produce far better results.

You dont need to leave the United States to get expert treatment.The Innovative Cosmetic Surgery Center is a leader in stem cell therapies. Dr. Malan trains physicians from around the world in this and other procedures. Our treatments are performed according to FDA standards in our Scottsdale clinic. Your safety and comfort are our foremost concern.

Arizona is the ideal location for a medical vacation. We offer free virtual consultations to discuss your concerns and treatment options. Dr. Malan hosts men from all over the United States for the treatment of erectile dysfunction. Explore your options. Call us at (480) 998-7999 or request an appointment online.

If youve been suffering from erectile dysfunction, now is the time to do something about it. Stem cell therapy is highly effective, minimally invasive and completely safe for the treatment of ED. We routinely host men from all over the United States and will help coordinate the details of your travel if you are out of state.

Call us today for a consultation (480) 998-7999 or request an appointment online.

More here:
Stem Cell Therapy for Erectile Dysfunction | Stem Cell ...

Stem Cell Therapy for Knee Pain – Vitality Medical Centers

For many patients with debilitating knee pain, treatment options are limited: steroid injections, high doses of pain medications, bracing and ultimately joint replacement surgery. In the last few years, innovative treatment options like stem cell injections are now being used to successfully treat patients with a multitude of degenerative orthopedic conditions.

How does stem cell therapy work and what benefits does stem cell therapy offer?

Stem cell therapy is a regenerative injection technique that infuses a damaged joint with stem cells, as well as the other components: growth factors that stimulate tissue growth, hyaluronic acid (a natural joint lubricant/buffer that improves mobility), and naturally occurring anti-inflammatory agents such as cytokines et. al. While this matrix has anti-inflammatory properties, much like cortisone and steroid shots, the beneficial effects of stem cell therapy goes well beyond the benefits and capabilities of standard injection therapy. Stem cell injections also have antimicrobial (germ-killing) and anti-fibrotic (i.e. ability to break down scar tissue) properties as well.

Injectable steroids and oral or topical pain medications only provide temporary pain relief and to nothing to address the underlying problem; stem cells restore damaged tissue while providing pain relief. The growth factors in stem cells may replace damaged cells in your body.

Are stem cell injections safe?

While there are risks with any procedure that involves injections, the laboratory that Vitality Medical Centers uses for their stem cells has a long history of stem cell injection procedures without a single reported adverse effect. There are, of course, always risks associated with any injection procedure (e.g. pain, bleeding, risk of infection, etc.) but sterile technique and administration by a trained physician minimizes these risks.

Am I a candidate for stem cell therapy?

Patients suffering from any kind of joint, tendon, or ligament pain may be potential candidates for stem cell therapy. Please keep in mind that not every patient is a reasonable candidate for stem cell therapy and that results from these injections may vary from no response to complete relief of symptoms. Upon evaluation, our physician may be able to provide you with alternative recommendations for treatment of particular conditions, such as physical therapy, viscosupplementation, prolotherapy or PRP (platelet rich plasma) injections, chiropractic care, etc.

What if I have a torn knee ligament?

Stem cell therapy can treat torn knee ligaments as long as there is not a complete tear. In cases where the tear is severe, but there are still some fibers attached, a higher number of injections may be required. Typically, the less severe the injury, the fast the healing time. Factors such as age, obesity, tobacco use, and other health factors can influence the number of injections needed as well as the healing time.

How long will it take me to recover?

The procedure itself takes about an hour in the office. After the procedure, tissue typically takes between one and three months to repair itself, but most patients will notice a change in their symptoms within one to two months. While the total number of injections required may vary depending on age and the type and severity of the condition, most patients require 2-4 sets of injections spaced apart.

See the article here:
Stem Cell Therapy for Knee Pain - Vitality Medical Centers

Stem Cell Hair Transplant: What Is It and When Will It Be …

A stem cell hair transplant is similar to a traditional hair transplant. But rather than removing a large number of hairs to transplant to the area of hair loss, a stem cell hair transplant removes a small skin sample from which hair follicles are harvested.

The follicles are then replicated in a lab and implanted back into the scalp in the areas of hair loss. This allows hair to grow where the follicles were taken from, as well as where theyre transplanted.

Stem cell hair transplants exist only in theory at the moment. Research is ongoing. Its estimated that stem cell hair transplants may be available by 2020.

Stem cells are cells that have the potential to develop into different types of cells found in the body. Theyre unspecialized cells that are unable to do specific things in the body.

However, theyre able to divide and renew themselves to either stay stem cells or become other types of cells. They help repair certain tissues in the body by dividing and replacing damaged tissues.

A stem cell hair transplant was successfully performed by Italian researchers in 2017.

The procedure begins with a punch biopsy to extract stem cells from the person. The punch biopsy is performed using an instrument with a circular blade thats rotated into the skin to remove a cylindrical sample of tissue.

The stem cells are then separated from the tissue in a special machine called a centrifuge. It leaves a cell suspension thats then injected back into the scalp in the areas of hair loss.

There are several different research teams working on stem cell hair loss treatments. While the procedures may vary slightly, theyre all based on growing new hair follicles in a lab using a small skin sample from the patient.

Currently, there are some clinics offering a version of stem cell hair transplants to the public. These arent approved by the U.S. Food and Drug Administration (FDA). Theyre considered investigational.

In 2017, the FDA released a warning about stem cell therapies. The warning advises anyone considering stem cell therapies to choose those that are either approved by the FDA or being studied under an Investigational New Drug Application (IND). The FDA authorizes INDs.

These procedures are performed in-office on an outpatient basis. They entail removing fat cells from the persons abdomen or hip using a liposuction procedure under local anesthesia.

A special process is used to remove the stem cells from the fat so that they can be injected into the scalp. This procedure takes approximately 3 hours.

The clinics that currently offer this procedure cant provide a guarantee for the outcome of the procedure. The results, if any, can vary from person to person. It may require several treatments over many months to see results.

Some research has found stem cell hair transplants can be effective in treating different hair loss conditions, including:

Some pain following the procedure is expected. It should subside within a week.

No recovery time is required, though excessive exercise should be avoided for a week. Some scarring can be expected where the fat has been removed.

You wont be able to drive yourself home following the procedure because of the effects of the local anesthesia.

Theres very little information available about the possible side effects of stem cell hair transplants. As with any medical procedure, theres always the risk of bleeding or infection at the site of the sample and the injection. Scarring is also possible.

Though complications from a punch biopsy are rare, theres a small risk of damage to the nerves or arteries beneath the site. Liposuction can also cause the same side effects and complications.

The research available on the success rate of stem cell hair transplants is very promising. The results of the Italian study showed a 29 percent increase in hair density 23 weeks after the last treatment.

The clinics that currently offer stem cell hair therapies not approved by the FDA dont make any guarantees in regard to results or success rates.

The cost of stem cell hair transplants hasnt been determined since theyre still in the research stages.

Some of the investigational stem cell hair replacement therapies being offered by various clinics range from approximately $3,000 to $10,000. Final cost depends on the type and extent of the hair loss being treated.

The stem cell hair transplant treatments being researched are expected to be available to the public by 2020. Stem cell hair transplants offer options to people who arent candidates for the hair loss treatments currently available.

While some clinics are offering stem cell hair replacement therapies, these are considered investigational and havent been approved by the FDA.

Continued here:
Stem Cell Hair Transplant: What Is It and When Will It Be ...

SELLAS Positive Trial Data, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha

SELLAS Life Sciences Announces Positive Readout for Leukemia Drug

SELLAS Life Sciences' (SLS) stock shot up as the company reported positive results from its Phase 1/2 study of its Galinpepimut-S treatment for patients with acute myeloid leukemia. The trial demonstrated that the patients treated with the drug candidate showed significant improvement in the survival rate. The median overall survival stood at 21 months while median follow-up remained at 30.8 month, in comparison to 5.4 months in patients treated with best standard care.

SELLAS had earlier reported initial data from the Phase 1/2 study of GPS. The median follow up in that read out was at 19.3 months, while median Overall Survival was 16.3 months, in comparison to 5.4 months in patients given best standard therapy. Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, said, Were extremely pleased with this follow-up data, which show that GPS may have potential as a longer-term therapy for AML patients in CR2, an aggressive disease where the majority of patients typically relapse and have a survival rate of approximately 5 months with best standard therapy.

SELLAS is currently working towards recruiting patients for the ongoing Phase 3 REGAL study. It is a 1:1 randomized, open label study which compares GPS monotherapy in the maintenance setting to investigators choice of best available treatment. The trial is aimed at AML patients with hematologic complete remission, with or without thrombocytopenia (CR2/CR2p), after second-line antileukemic therapy. These patients have been found ineligible for or unable to undergo allogeneic stem-cell transplantation. The primary endpoint of the study is related to Overall Survival from the time of study entry whereas the secondary endpoints are related to antigen-specific T-cell immune response dynamics, leukemia-free survival and measurable residual disease by multigene array among others.

In January, the company provided highlights of its clinical development progress and upcoming catalysts during 2020. SELLAS expects to release interim analysis of the Phase 1/2 basket study of GPS with pembrolizumab in multiple tumor types during the second half of 2020. It also anticipates receiving guidance from the FDA on the regulatory and development pathway for NPS in TNBC patients in the first quarter of 2020.

For its third quarter, the company had reported its research and development expenses at $1.8 million, up from $1.7 million it had spent during the third quarter of the previous year. Its general and administrative expenses for the quarter were reported at $2.4 million while the corresponding figure for the previous year quarter was at $1.3 million. SELLAS reported its cash and cash equivalent at $9.1 million as of September 30, 2019. The company announced that its net loss attributable to common stockholders was $11.5 million while its net loss for the third quarter of the previous year was at $9.4 million. The net loss for the nine months stood at $20.5 million, down from $27.9 million in net loss for the corresponding time period of the past year.

SELLAS had a turbulent past year when its stock tumbled more than 97 percent in the stock market. The latest positive news is expected to bring some respite; however, investors are still advised to remain cautious. One of the biggest concerns about the company is its lack of income stream. The company has yet to report any revenue. SELLAS has robust drug pipeline with several ongoing trials. It is testing GPS in combination with Keytruda as a basket study for 5 indications. It is also working on testing drug candidate for treating Malignant Pleural Mesothelioma and Multiple Myeloma. SELLAS has NPS clinical trials going on for breast cancer as well.

Endo International (ENDP) reported its fourth-quarter results where it surpassed revenue and net income estimates. The company announced its EPS at $0.74, beating consensus estimate of $0.57. Its revenue for the quarter stood at $764.8 million, surpassing the market estimate of $731.43 million. However, its revenue dropped 3 percent on a year-over-year basis as it had earned $786 million in revenue during the fourth quarter of the previous year.

Endo also provided segment wise update where its revenue from the Sterile Injectables segment increased by 10% to $285 million. The increase was mainly due to the continued robust growth of Vasostrict and Adrenalin. The companys Generic Pharmaceuticals revenues dipped 14% due to the competitive pressure on generic products.

Endo provided guidance for FY 2020 as it expects its total revenue to be in the range of $2.72 billion and 2.92 billion. Its adjusted EPS from continuing operations will likely be between $2.15 and $2.40. The consensus estimates for EPS stands at $2.25 while revenue is expected to be $2.90 billion. Paul Campanelli, Chairman, President and Chief Executive Officer at Endo, said, In 2019, Endo delivered stronger than expected performance during the fourth quarter and for the full year, driven by continued double-digit percentage revenue growth in our Sterile Injectables segment and in the Specialty Products Portfolio of our Branded Pharmaceuticals segment, and as a result of our dedication to operational execution.

Endo is engaged in the development and marketing of branded and generic pharmaceuticals in the United States. The company has strong pipeline and has multiple trials going on for treating different ailments. Some of its most prominent products are Testopel, Fortesta and Xiaflex.

Menlo Therapeutics (MNLO) announced that its Phase 2 clinical for treating chronic pruritus of unknown origin failed to meet its primary endpoint. The trial involved patients treated with one a day daily oral serlopitant. The data demonstrated that there was no meaningful difference between the placebo group and serlopitant group. The main purpose of the study was to demonstrate reduction in itching as measured by a rating scale.

The study showed that 37.9 percent of patients treated with serlopitant achieved a 4 point or greater improvement on the rating scale. However, the placebo group showed 39.3 percent of patients hitting that mark. The placebo group also showed 10 percent higher response than in any of the previous studies testing the once-daily pill. The company CEO Steve Basta said that there is no such indication that such a high rate would be replicated in future studies. He added, That would be putting undue weight on the [chronic pruritus of unknown origin] results. I think what youll see is this is an outlier. He also said that, The higher placebo response rate may be due to characteristics of the CPUO population, which is not well understood clinically.

The company expects the results from Phase 3 trials for the treatment of pruritus associated with prurigo nodularis to be out in the months of March or April this year.

However, this is not the first time the placebo effect has disrupted serlopitant tests. The company suffered two mid-stage failures, involving the testing of drugs for managing itching in atopic dermatitis and chronic cough. These research and development measures will now likely take place under the management of Foamix. Menlo and Foamix have agreed for an all-stock merger, which was approved by Menlo shareholders in January. It is expected that the agreement will close on or around March 9, 2020.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Here is the original post:
SELLAS Positive Trial Data, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

‘Survivor 40’: Why Ethan Zohn Doesn’t Think it Was a Smart Idea to Return for ‘Winners at War’ – Showbiz Cheat Sheet

Who doesnt love a good redemption story? Survivor: Winners at War was designed to bring former Survivor winners together and give them another chance at glory, but there is one winner in particular who this season is especially sweet for. Ethan Zohn won the competition in 2001 and then competed on the All-Stars season in 2004. Now, hes back for Winners at War after a 15-year hiatus. During that break from tv, Zohns real life became a game of Survivor, so he originally didnt think that returning to the actual show was the greatest idea.

In 2009, Zohn was diagnosed with CD20-positive Hodgkins lymphoma. After a year of treatment, he went into remission. But his battle wasnt over. Over a year and a half later, the cancer came back in his chest. In 2013, he beat the cancer again and went into remission.

After getting healthy, he was invited to come back to Survivor in 2016 but turned it down.

After beating cancer twice, Zohn felt it was time to come back and play the game again.

The fact that I was part of this show way back in the day and had the opportunity to play again, for me, it was a huge gift, he told Entertainment Tonight. Ive been through some health challenges and Iremember sitting in the hospital room watchingHeroes vs. Villains, getting my second stem cell transplant and dreaming to myself that someday Id be healthy enough mentally, physically, spiritually to be able to go playSurvivoragain. When they called for season 40, I instantly said yes because it was just getting to this point in my life, to be able to go playSurvivorfor me was, like, thats winning for me.

But going into the game this time was different than Zohns previous two stints on the show as his mindset had changed.

Having gone through such a major health challenge and recovering from that [was hard], he said. Going through cancer isdifficult but for me, personally, it was the after-effects that was the most difficult. Im a giant ball of anxiety. I live in fear that my cancer is going to come back for a third time, and it just does something to you.

Zohn was able to use the fact that people underestimated him to his advantage. No one knew that much about him as he hadnt played the game in over a decade. He was, however, voted out in the third episode.

Despite enjoying playing in Winners at War, Zohn doesnt think hell compete again.

I dont think I dont know! he said when asked if he would do Survivor again. Its so I just want to put into perspective where, and Im not trying to be the poor me, crying B, but building yourself back up after cancer isa difficult process. AndSurvivor, the game itself, there are moments like I said, I was afraid to go out there without my toolkit that I had and I just didnt know what it would do to me but it screws you up mentally and physically and spiritually and socially. It messes you up.

I just dont know at this age, and what Ive been through health-wise, that I could ever really I dont think it would be a smart decision to go, he continued. I dont think it was a smart decision to play this time, but I think it would be an even worse decision to go next time, health-wise.

See more here:
'Survivor 40': Why Ethan Zohn Doesn't Think it Was a Smart Idea to Return for 'Winners at War' - Showbiz Cheat Sheet

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market to Surge at a Robust Pace in Terms of Revenue Over 2020 to 2025 – News Times

The Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market report by Globalmarketers.Biz sets out the production, consumption, revenue, gross margin, cost, gross, market share, CAGR, and global market influencing factors of the market for 2020-2025. The segmentation of regional market included the historical and forecast mandates for North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market report provides a far-reaching industry analysis by types, applications, players and regions.

Request a Sample PDF Copy of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Report Here: https://www.globalmarketers.biz/report/medicine/global-circulating-tumor-cells-(ctcs)-and-cancer-stem-cells-(cscs)-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/132195 #request_sample

The Top Key Players Are Covered In This Report Are As Follows:

JanssenQiagenAdvanced Cell DiagnosticsApoCellBiofluidicaClearbridge BiomedicsCytoTrackCelseeFluxionGilupiCynvenioOn-chipYZY BioBioViewFluidigmIkonisysAdnaGenIVDiagnosticsMiltenyi BiotecScreenCellSilicon Biosystems

Above are the leading companies and brands that are driving the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. The CAGR numbers are looking quite impressive for the forecast period of 2020-2025 in the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market. The sales, import, export and revenue figures are also skyrocketing in the forecast period. The key players and brands are making their moves by product launches, their researches, their joint ventures, merges, and accusations and are getting successful results. Complete study compiled with over 100+ pages, list of tables & figures, profiling 10+ companies.

Market Segment by Type, covers

CellSearchOthers

Market Segment by Applications, can be divided into

Breast Cancer Diagnosis and TreatmentProstate Cancer Diagnosis and TreatmentColorectal Cancer Diagnosis and TreatmentLung Cancer Diagnosis and TreatmentOther Cancers Diagnosis and Treatment

Market Segment by Regions, regional analysis covers

Enquiry before Buying At https://www.globalmarketers.biz/report/medicine/global-circulating-tumor-cells-(ctcs)-and-cancer-stem-cells-(cscs)-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/132195 #inquiry_before_buying

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Report Structure at a Glance:

Reasons to Purchase this Report :

Table of Content:

Get Detailed Table Of Cotents : https://www.globalmarketers.biz/report/medicine/global-circulating-tumor-cells-(ctcs)-and-cancer-stem-cells-(cscs)-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/132195 #table_of_contents

Do You Have Any Question Or Specific Requirement? Ask to Our Industry Expert @ [emailprotected]

Note : You Can Request for the Customisation of Particular Report as per Your Needs. We Ensure You That You Will Get Report As You Want. Thanking You!

More:
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market to Surge at a Robust Pace in Terms of Revenue Over 2020 to 2025 - News Times